Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in treatment-resistant IgA nephropathy
jRCT2043200002Phase 1Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in IgA nephropathy (IgAN), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Incidence of adverse events up to 6 weeks after the first dose. Started Oct 2020; status: completed.
02
Drugs
ADR-001
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2043200002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043200002.